lenvatinib用于甲状腺癌获得良好的疗效（SELECT研究）

2014-10-24 MedSci MedSci原创

Lenvatinib是一种口服多受体酪氨酸激酶(RTK)抑制剂，具有新颖的结合模式，除抑制参与肿瘤增殖的其他促血管生成和致癌信号通路相关RTK外，还能够选择性抑制血管内皮生长因子(VEGF)受体的激酶活性。目前，卫材也正在评估lenvatinib用于其他癌症的治疗。Lenvatinib在日本、美国、欧盟提交的申请文件，是基于III期SELECT研究的积极顶线数据。该研究是一项多中心、随机、双盲、安

Lenvatinib是一种口服多受体酪氨酸激酶(RTK)抑制剂，具有新颖的结合模式，除抑制参与肿瘤增殖的其他促血管生成和致癌信号通路相关RTK外，还能够选择性抑制血管内皮生长因子(VEGF)受体的激酶活性。目前，卫材也正在评估lenvatinib用于其他癌症的治疗。

Lenvatinib在日本、美国、欧盟提交的申请文件，是基于III期SELECT研究的积极顶线数据。该研究是一项多中心、随机、双盲、安慰剂对照III期研究，调查了口服lenvatinib(24mg)治疗放射性碘131抵抗的分化型甲状腺癌(RR-DTC)的疗效，主要终点为无进展生存期(PFS)，次要终点包括总缓解率(ORR)，总生存期(OS)和安全性。数据表明，与安慰剂组相比，lenvatinib治疗组无进展生存期(PFS)显著延长(18.3个月 vs 3.6个月，p<0.0001)，达到了研究的主要终点。

据估计，在美国，2012年新增甲状腺癌患者5.2万例。目前，尽管大多数类型的甲状腺癌能够治疗，但复发性甲状腺癌鲜有治疗方案，因此存在显著未获满足的医疗需求。

相关研究：

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y.Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. doi: 10.1155/2014/638747.

Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S.Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep;24(9):2256-61

Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun;99(6):2086-94

Stjepanovic N, Capdevila J.Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 2014 Apr 10;8:129-39.

Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M.Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11; 11:349.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=72494, encodeId=7257e24943e, content=不错medsci让我学习很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793708, encodeId=9a3d1e9370892, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Apr 16 04:53:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12813, encodeId=36c812813fe, content=甲状腺癌希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Thu Nov 27 22:27:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464238, encodeId=a59e1464238f6, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10812, encryptionId=90b91081205, topicName=lenvatinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b506628012, createdName=tastas, createdTime=Sun Oct 26 14:53:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
2016-03-22 Gsurgeon

不错medsci让我学习很多

178 0
[GetPortalCommentsPageByObjectIdResponse(id=72494, encodeId=7257e24943e, content=不错medsci让我学习很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793708, encodeId=9a3d1e9370892, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Apr 16 04:53:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12813, encodeId=36c812813fe, content=甲状腺癌希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Thu Nov 27 22:27:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464238, encodeId=a59e1464238f6, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10812, encryptionId=90b91081205, topicName=lenvatinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b506628012, createdName=tastas, createdTime=Sun Oct 26 14:53:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
2015-04-16 zhangxingru

#SeLECT#

111 0
[GetPortalCommentsPageByObjectIdResponse(id=72494, encodeId=7257e24943e, content=不错medsci让我学习很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793708, encodeId=9a3d1e9370892, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Apr 16 04:53:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12813, encodeId=36c812813fe, content=甲状腺癌希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Thu Nov 27 22:27:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464238, encodeId=a59e1464238f6, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10812, encryptionId=90b91081205, topicName=lenvatinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b506628012, createdName=tastas, createdTime=Sun Oct 26 14:53:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
2014-11-27 jawel

甲状腺癌希望

157 0
[GetPortalCommentsPageByObjectIdResponse(id=72494, encodeId=7257e24943e, content=不错medsci让我学习很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:06:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793708, encodeId=9a3d1e9370892, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Apr 16 04:53:00 CST 2015, time=2015-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12813, encodeId=36c812813fe, content=甲状腺癌希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Thu Nov 27 22:27:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464238, encodeId=a59e1464238f6, content=<a href='/topic/show?id=90b91081205' target=_blank style='color:#2F92EE;'>#lenvatinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10812, encryptionId=90b91081205, topicName=lenvatinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b506628012, createdName=tastas, createdTime=Sun Oct 26 14:53:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
2014-10-26 tastas

#lenvatinib#

62 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

lenvatinib用于甲状腺癌获得良好的疗效（SELECT研究）

相关资讯

科室

工具

服务